Premium
Time‐dependent benefits of pre‐treatment with new oral P2Y 12 ‐inhibitors in patients addressed to primary PCI for acute ST‐elevation myocardial infarction
Author(s) -
Pepe Martino,
Cafaro Alessandro,
Paradies Valeria,
Signore Nicola,
Addabbo Francesco,
Bortone Alessandro Santo,
Navarese Eliano Pio,
Contegiacomo Gaetano,
Forleo Cinzia,
Bartolomucci Francesco,
Di Cillo Ottavio,
Bianchi Francesco Paolo,
Zanna Domenico,
Favale Stefano
Publication year - 2019
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27863
Subject(s) - medicine , timi , conventional pci , ticagrelor , prasugrel , percutaneous coronary intervention , myocardial infarction , cardiology , clopidogrel , p2y12 , observational study
Objectives The aim of this observational study was to determine the benefits of the novel, orally delivered P2Y 12 ‐inhibitors (Is) in terms of angiographic endpoints and in relation to the time of the loading dose (LD) administration. Background The goal of ST‐elevation myocardial infarction (STEMI) treatment is timely reperfusion. The P2Y 12 ‐Is prasugrel and ticagrelor have improved the angiographic outcome of primary percutaneous coronary intervention (pPCI) and patients' prognosis. However, their onset of action is impaired in STEMI and delayed by their oral administration. Methods The 328 eligible patients with STEMI consecutively referred for pPCI were divided into three groups depending on the interval of “P2Y 12 ‐I LD administration‐to‐balloon time”: Group 2 included patients that received P2Y 12 ‐I LD at least 60 min prior to pPCI, Group 1 within 60 min prior to pPCI, and Group 0 at the moment of pPCI. Angiographic, clinical, and biochemical parameters were evaluated. Pre‐ and post‐pPCI TIMI flow grade (TFG) and ST resolution (STR) were used as outcome measures to determine efficacy and optimal timing of pretreatment. Results Pre‐pPCI TFG improved with increasing P2Y 12 ‐I LD administration‐to‐balloon time; pre‐PCI TFG 0/1 was 74.5% in Group 0, 65.5% in Group 1 and 54.9% in Group 2 ( P < 0.002). Post‐pPCI TFG 3 results also differed significantly between the three groups: 85.2% in Group 0, 88.1% in Group 1, 97.6% in Group 2 ( P < 0.013). ST resolution rates were also positively associated with longer pretreatment intervals. Conclusions This observational study suggests that the angiographic benefit of P2Y 12 ‐I administration is time‐dependent: longer pretreatment improves coronary reperfusion in terms of pre‐ and post‐pPCI TFG and STR.